| Carboplatin/paclitaxel | Carboplatin/gemcitabine | Carboplatin/pemetrexed | Carboplatin/paclitaxel/bevacizumab | |
| HTN | 37.7% | 37.1% | 56.0% | 25.0% |
| DM | 8.5% | 17.1% | 28.0% | 3.6% |
| COPD | 23.6% | 22.9% | 32.0% | 17.9% |
| CAD | 11.3% | 17.1% | 16.0% | 3.6% |
| Renal Disease | 2.8% | 2.9% | 0.0% | 0.0% |
| Liver Disease | 0.9% | 0.0% | 12.0% | 0.0% |